We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has granted priority review status to Elan and Biogen Idec’s supplemental biologics license application (sBLA) for Tysbari, clearing the way for the agency to issue a decision on the drug by late March 2006.